Center-Authored Papers

Filters: Author is Kraft, George H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA.  2008.  Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain : a journal of neurology. 131(Pt 2):e89;authorreplye90.
B
Wundes A, Bowen JD, Kraft GH, Maravilla KR, McLaughlin B, von Geldern G, Georges G, Nash RA, Lu J-Q.  2017.  Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis.. Journal of the neurological sciences. 373:339-341. Abstract
H
Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT, Freedman MS, Kraft GH, Mancardi GL, Martin R et al..  2010.  Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(8):1076-83. Abstract
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH et al..  2017.  High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.. Neurology. Abstract
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
M
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract